The U.S. House of Representatives today passed an FY 18 federal budget, which includes; a $3 billion increase for medical research at the National Institutes of Health (NIH)—the largest such funding increase in 15 years; and a $275 million increase for the National Cancer Institute (NCI).
The House of Representatives tonight passed legislation that would change the process for accessing experimental drugs without including necessary patient safeguards. The Right-to-Try legislation was opposed by the American Cancer Society Cancer Action Network (ACS CAN) along with more than 80 other organizations representing millions of patients.
Twenty organizations representing millions of patients and consumers across the country sent a letter to the Secretaries of Health and Human Services, Labor and Treasury urging the administration to address patient concerns before finalizing troubling rules that as currently drafted would undermine access to affordable, comprehensive health coverage.
Food and Drug Administration (FDA) Commissioner Scott Gottlieb today announced an Advanced Notice of Proposed Rulemaking (ANPRM) aimed at assessing the role of flavoring in tobacco initiation, use and cessation.
Food and Drug Administration (FDA) Commissioner Scott Gottlieb today announced an Advanced Notice of Proposed Rulemaking (ANPRM) aimed at reducing nicotine levels in cigarettes to levels that no longer cause or sustain addiction.
Two reports released today highlight potentially dangerous findings among U.S. middle and high school students when it comes to advertising and perceptions of electronic cigarette and other tobacco products.
The House of Representatives tonight rejected legislation that would have changed the process for accessing experimental drugs without including necessary patient safeguards. The Right-to-Try legislation was opposed by the American Cancer Society Cancer Action Network (ACS CAN) along with more than 85 other organizations representing millions of patients.
The American Cancer Society Cancer Action Network together with more than 75 organizations representing millions of patients sent a letter to leadership in the U.S. House of Representatives, expressing concerns about proposed legislation to change the process for accessing experimental drugs without including necessary patient safeguards.
The administration clarified that an Idaho bulletin permitting the sale of health insurance products that don’t meet required consumer protections and discriminate against those with pre-existing conditions would be in violation of the federal health care law.
The American Cancer Society Cancer Action Network (ACS CAN) submitted comments to the Department of Labor regarding proposed changes to rules governing association health plans (AHPs). The comments detail several ways the proposed rule could divide the individual insurance market and significantly weaken patient protections leaving cancer patients and survivors with few meaningful or affordable coverage choices.